Sector News

Rasna Therapeutics goes public with reverse merger deal

August 17, 2016
Life sciences

Leukemia and lymphoma biotech Rasna Therapeutics has pulled off a reverse merger with an unlikely partner as it plans to list on the OTC Markets under the symbol “ATVM.”

The reverse merger, which more quickly propels the formerly private biotech into the public sphere, has been done through Active With Me–a Canadian company that offers online information on activity-based travel to travelers.

The two are strange bedfellows, given that U.K.-based Rasna Therapeutics works on cancer drugs, but the deal has now been finalized and allows the biotech to trade its shares publicly, with the combined company to be named Rasna Therapeutics.

The early-stage biotech is currently working on modulating the molecular targets LSD1 and NPM1, which are implicated in the progression of both leukemia and lymphoma.

“Becoming a public company is a key element of our growth strategy, and the completion of this reverse merger is a significant accomplishment for Rasna Therapeutics,” said James Tripp, acting CEO of Rasna.

“We believe that this breakthrough program may have significant benefits across all forms of leukemia. Our NPM1 program targets the sub-set of acute myeloid leukemia patients with the NPM1 mutation and may also benefit the general AML population. We are aiming to have a lead candidate identified by 2017.”

Rasna was formed in 2013 by biotech entrepreneur Gabriele Cerrone together with Dr. Roberto Pellicciari, a medicinal chemist and the scientific founder of Intercept Pharmaceuticals ($ICPT), and Dr. Brunangelo Falini, a physician and hematologist.

By Ben Adams

Source: Fierce Biotech

comments closed

Related News

July 14, 2024

Flagship raises $3.6B for biotech investing

Life sciences

Flagship Pioneering said Wednesday that it’s added another $3.6 billion to its capital base, bringing the total raised since 2021 to $6.4 billion. Meanwhile, Flagship announced more than a dozen promotions and new hires in its leadership ranks. The changes include the promotions of Lovisa Afzelius and Paul Biondi to general partner and the addition of Dina Ciarimboli as general counsel and executive partner.

July 14, 2024

Mikael Dolsten set to leave Pfizer, sparking search for CSO successor

Life sciences

After 15 years at Pfizer, including a career-defining pandemic period, the chief scientific officer will leave the Big Pharma once the drugmaker finds his successor. Dolsten joined Pfizer when the company closed a megamerger with Wyeth in 2009. Pfizer made Dolsten president of worldwide R&D the following year. The executive has stayed at the top of Pfizer’s R&D tree ever since.

July 14, 2024

CDMO Lotte breaks ground on $3.3B production plant in Korea, touts growth goals

Life sciences

Late last week, Lotte Biologics broke ground on its flagship facility at the Songdo Bio Campus in Incheon International City, South Korea. The company is pitching the production effort as a key part of its quest to become one of the top 10 contract development and manufacturing organizations (CDMOs) in the world, Lotte said in a press release.

How can we help you?

We're easy to reach